|
US6110898A
(en)
*
|
1996-05-24 |
2000-08-29 |
University Of Maryland, Baltimore |
DNA vaccines for eliciting a mucosal immune response
|
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
|
JP2001516729A
(ja)
*
|
1997-09-15 |
2001-10-02 |
ジェネティック・イミューナティ・リミテッド・ライアビリティ・カンパニー |
皮膚の抗原提示細胞に遺伝子を運搬する方法
|
|
AU749059B2
(en)
*
|
1997-12-12 |
2002-06-20 |
Cell Genesys, Inc. |
Therapeutic use of lentiviral vectors
|
|
AU6761198A
(en)
*
|
1998-03-17 |
1999-10-11 |
Julianna Lisziwiewicz |
Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
|
|
US6461616B1
(en)
*
|
2000-09-09 |
2002-10-08 |
Akzo Nobel Nv |
EIAV p26 deletion vaccine and diagnostic
|
|
US20070025958A1
(en)
|
2000-10-27 |
2007-02-01 |
Hadden John W |
Vaccine immunotherapy
|
|
CA2950109C
(en)
|
2000-10-27 |
2019-02-19 |
John W. Hadden |
Vaccine immunotherapy for immune suppressed patients
|
|
US7097842B2
(en)
|
2000-11-23 |
2006-08-29 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
PL212047B1
(pl)
|
2000-11-23 |
2012-08-31 |
Bavarian Nordic As |
Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
|
|
US7628980B2
(en)
|
2000-11-23 |
2009-12-08 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
|
ES2310201T3
(es)
|
2001-02-13 |
2009-01-01 |
Government Of The United States Of America, As Represented By The Secretary Of The Army |
Vacuna para inmunizacion transcutanea contra la diarrea de los viajeros.
|
|
EP2345665A3
(en)
|
2001-12-04 |
2012-02-15 |
Bavarian Nordic A/S |
Flavivirus NS1 subunit vaccine
|
|
NZ536592A
(en)
|
2002-04-19 |
2007-01-26 |
Bavarian Nordic As |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
JP2005537793A
(ja)
|
2002-09-05 |
2005-12-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法
|
|
EP1590432A4
(en)
*
|
2003-01-15 |
2008-05-14 |
Res Inst For Genetic And Human |
DNA COMPOSITION AND ITS USE
|
|
FR2872170B1
(fr)
|
2004-06-25 |
2006-11-10 |
Centre Nat Rech Scient Cnrse |
Lentivirus non interactif et non replicatif, preparation et utilisations
|
|
EP1797189A4
(en)
*
|
2004-09-02 |
2010-05-19 |
Qun Chen |
ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES
|
|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
EP2150618B1
(en)
|
2007-05-04 |
2017-10-11 |
University Health Network |
Il-12 immunotherapy for cancer
|
|
WO2009070639A1
(en)
|
2007-11-28 |
2009-06-04 |
Irx Therapeutics, Inc. |
Method of increasing immunological effect
|
|
WO2010009465A2
(en)
*
|
2008-07-18 |
2010-01-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Htlv-ii vector and methods of use
|
|
MX2011012147A
(es)
|
2009-05-15 |
2012-06-19 |
Irx Therapeutics Inc |
Inmunoterapia de vacuna.
|
|
CN103097543A
(zh)
|
2009-12-08 |
2013-05-08 |
伊尔克斯治疗有限公司 |
逆转朗格汉斯细胞免疫抑制的方法
|